Arbutus Biopharma (Arbutus Biopharma) Total Inventories : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Arbutus Biopharma Total Inventories?

Arbutus Biopharma's total inventories for the quarter that ended in Dec. 2023 was $0.00 Mil. Arbutus Biopharma's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Arbutus Biopharma's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $0.52.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Arbutus Biopharma's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.00.

Arbutus Biopharma Total Inventories Historical Data

The historical data trend for Arbutus Biopharma's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Total Inventories Chart

Arbutus Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

Arbutus Biopharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Inventories	Get a 7-Day Free Trial															-	-	-	-	-

Arbutus Biopharma Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Arbutus Biopharma (NAS:ABUS) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Arbutus Biopharma's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(126.003	+	0.75 * 1.776	+	0.5 * 0	-	38.383
-	0	-	0)	/	169.867
=	0.52

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Arbutus Biopharma's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Arbutus Biopharma's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Arbutus Biopharma's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	0	/	2.145
	=	0.00

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Arbutus Biopharma Total Inventories Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Arbutus Biopharma (Arbutus Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (NAS:ABUS) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

I9DN:Germany

Address

701 Veterans Circle, Warminster, PA, USA, 18974

Website

http://www.arbutusbio.com

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Executives

Melissa Rewolinski	director	9000 STATE ROAD, PHILADELPHIA PA 19136
Karen Sims	officer: Chief Medical Officer	701 VETERANS CIRCLE, WARMINSTER PA 18974
J. Christopher Naftzger	officer: General Counsel and CCO	633 LOWTHER ROAD, LEWISBERRY PA 17339
Michael J. Sofia	officer: Chief Scientific Officer	C/O ARBUTUS BIOPHARMA CORP., SUITE 100, 8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Tram Tran	director	C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Roivant Sciences Ltd.	10 percent owner	CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Michael J. Mcelhaugh	officer: Chief Business Officer	C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Eric Venker	director	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
James R Meyers	director	GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Andrew Cheng	director	170 HARBOR WAY, 3RD FLOOR, C/O AKERO THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Myrtle S Potter	director	10 FINDERNE AVE, BRIDGEWATER NJ 08807
William H. Collier	director, officer: President and CEO	C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Elizabeth Howard	officer: Executive VP & General Counsel	100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
David C Hastings	officer: Chief Financial Officer	C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Gaston Picchio	officer: Chief Development Officer	C/O ARBUTUS BIOPHARMA CORP, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8